BioTelemetry (BEAT) Reports In-Line Q1 EPS

BioTelemetry (NASDAQ: BEAT) reported Q1 EPS of $0.16, in-line with the analyst estimate of $0.16. Revenue for the quarter came in at $55.9 million versus the consensus estimate of $55.57 million.

For earnings history and earnings-related data on BioTelemetry (BEAT) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Arrive AI and DXC Technology partner to bring delivery tech to factories
• Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss of $0.75/sh